What are the treatment options for advanced metastatic ovarian cancer

Treatment Options for Advanced Metastatic Ovarian Cancer

Advanced metastatic ovarian cancer—where the cancer has spread beyond the ovaries—is treated with a combination approach. Let me walk you through how doctors typically think about this and what options exist.

How Doctors Approach Advanced Ovarian Cancer

According to the NCCN Guidelines for Ovarian Cancer, the standard treatment strategy for advanced disease involves two main phases:

1. Surgery first (when possible) to remove as much cancer as possible
2. Chemotherapy to treat any remaining cancer cells

The Two-Part Treatment Approach

Surgery (Cytoreductive Surgery)

If you're able to have surgery, a gynecologic oncologist (a surgeon specializing in gynecologic cancers) will attempt debulking or cytoreductive surgery. This means removing as much visible cancer as possible. For advanced disease, this may involve:

• Removing both ovaries, fallopian tubes, and uterus
• Removing all or part of nearby organs affected by cancer
• Removing lymph nodes that appear abnormal or enlarged

The goal is to remove all visible cancer, which helps chemotherapy work more effectively.

Chemotherapy

Platinum-based chemotherapy is the standard first-line treatment. The typical regimen combines:

• Paclitaxel (a drug that stops cancer cells from dividing)
• Carboplatin (a platinum-based drug that damages cancer cell DNA)

This combination is given every 3 weeks for multiple cycles.

Adding Targeted Therapy: Bevacizumab

For advanced ovarian cancer, bevacizumab (Avastin) is often added to chemotherapy. This is an anti-angiogenesis drug, meaning it blocks the formation of new blood vessels that tumors need to grow. Research shows this combination improves outcomes for advanced disease.

Maintenance Therapy (After Initial Treatment Works)

This is an important part of treatment for advanced ovarian cancer. If your cancer responds well to initial chemotherapy, maintenance therapy may continue the fight:

PARP Inhibitors

If your tumor has a BRCA mutation or HRD-positive status (homologous recombination deficiency—meaning your cancer cells have difficulty repairing DNA damage), PARP inhibitors are preferred options:

• Olaparib (can be given alone for up to 2 years, or combined with bevacizumab for up to 15 months)
• Niraparib (can be given for up to 3 years)
• Rucaparib (can be given for up to 2 years)

These drugs work by blocking a protein (PARP) that cancer cells use to repair DNA, making them more vulnerable to death.

Bevacizumab Maintenance

If bevacizumab was part of your chemotherapy, it may be continued alone as maintenance therapy.

Biomarker Testing Guides Treatment

Before or during treatment, your tumor should be tested for specific biomarkers that may open additional treatment doors:

• BRCA mutations (inherited or in the tumor)
• HRD status (homologous recombination deficiency)
• HER2 expression
• Microsatellite instability (MSI)
• Mismatch repair (MMR) status
• Tumor mutational burden (TMB)
• BRAF mutations
• Folate receptor alpha (FRα)

According to the NCCN Guidelines, if certain biomarkers are present, targeted therapies or immunotherapy may become options.

If Cancer Returns (Recurrence)

If your cancer returns after initial treatment, the approach depends on platinum sensitivity:

Platinum-sensitive (returns more than 6 months after treatment):

• Platinum-based chemotherapy is typically recommended again
• Bevacizumab may be added
• PARP inhibitors may be an option if not previously used

Platinum-resistant (doesn't improve during treatment or returns within 6 months):

• Non-platinum chemotherapy is usually tried first
• Bevacizumab is a preferred option
• For tumors with high folate receptor alpha (FRα), mirvetuximab soravtansine-gynx (Elahere) is preferred—this is an antibody-drug conjugate that targets cancer cells
• Biomarker-directed therapies or immunotherapy may be options

Clinical Trials

The NCCN Guidelines strongly encourage all patients with advanced or recurrent ovarian cancer to consider clinical trials, as they may offer access to newer treatment approaches.

Questions to Ask Your Oncology Team

To help you engage in shared decision-making about YOUR specific situation:

1. Based on my cancer stage and biomarker testing, which chemotherapy regimen do you recommend, and why?
2. Should bevacizumab be added to my chemotherapy, and what are the potential benefits and side effects?
3. What biomarker testing has been done on my tumor, and are there targeted therapies I'm eligible for?
4. If my cancer responds well to initial treatment, what maintenance therapy options are available for me?
5. Are there clinical trials available that match my specific cancer type and biomarkers?

Important Reminder

Your oncologist will determine the most appropriate treatment approach for YOUR specific case based on your complete clinical picture—including your overall health, cancer stage, biomarker results, and personal goals. The treatment landscape for ovarian cancer is evolving, and your care team will recommend the approach most likely to help you.

---

This information is for educational purposes only. Always consult your healthcare team for personalized medical advice and decisions.